Fig. 1From: Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world studyAdverse events depending on patient characteristics. Patients’ characteristics like sex, medication-overuse headache and aura. Proportion of patients with the respective characteristics who reported AEsBack to article page